.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH51_SitagliptinAndSimvastati.SitagliptinAndSimvastati .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH51_SitagliptinAndSimvastati.SitagliptinAndSimvastati| name: | SitagliptinAndSimvastatin | |
| ATC code: | A10BH51 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 198 | L |
| clearance: | 192 | mL/min |
| other parameters in model implementation | ||
Sitagliptin and simvastatin is a fixed-dose combination drug approved for use in the management of type 2 diabetes mellitus and dyslipidemia. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control, while simvastatin is a HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular risk. This combination allows for convenient co-administration to patients requiring both glycemic and cholesterol management.
No published population pharmacokinetic parameters are available specifically for the fixed-dose combination of sitagliptin and simvastatin (ATC A10BH51). Below are estimated parameters based on available data for the individual monotherapies in healthy adults receiving typical oral doses.